We are live on ! Find out more
ACAD icon

Acadia Pharmaceuticals
ACAD

212 hedge funds and large institutions have $4.44B invested in Acadia Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 72 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

33% more capital invested

Capital invested by funds: $3.34B → $4.44B (+$1.1B)

4% more funds holding

Funds holding: 203 → 212 (+9)

7% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 72

1.9% less ownership

Funds ownership: 98.15% → 96.25% (-1.9%)

38% less call options, than puts

Call options by funds: $44.1M | Put options by funds: $71.4M

Holders
212
Holders Change
+9
Holders Change %
+4.43%
% of All Funds
5.29%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
34
Increased
67
Reduced
72
Closed
24
Calls
$44.1M
Puts
$71.4M
Net Calls
-$27.2M
Net Calls Change
-$16.3M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$74.7M
2
BlackRock
BlackRock
New York
+$26M
3
TCIM
TIAA CREF Investment Management
New York
+$16.9M
4
TA
Teachers Advisors
New York
+$13.1M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$44.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
3
SIG
Senator Investment Group
New York
-$18.1M
4
Millennium Management
Millennium Management
New York
-$17.2M
5
ACA
Avoro Capital Advisors
New York
-$17.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
76
Polar Capital
United Kingdom
$2.83M -$3.25M -100,000 -57%
GBA
77
Garrison Bradford & Associates
New York
$2.76M -$16.3K -500 -0.7%
ProShare Advisors
78
ProShare Advisors
Maryland
$2.68M +$215K +6,600 +10%
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$2.53M +$84.2K +2,587 +4%
Millennium Management
80
Millennium Management
New York
$2.32M -$17.2M -527,253 -90%
QF
81
QVT Financial
New York
$2.28M -$1.99M -61,121 -50%
HI
82
Handelsinvest Investeringsforvaltning
Denmark
$2.21M – – –
DekaBank Deutsche Girozentrale
83
DekaBank Deutsche Girozentrale
Germany
$2.16M – – –
CCI
84
Columbus Circle Investors
$2.03M -$3.94M -121,165 -69%
EU
85
Emory University
Georgia
$2M -$128K -3,946 -7%
SBIA
86
Sheaff Brock Investment Advisors
Indiana
$1.88M -$32.5K -1,000 -2%
RJFSA
87
Raymond James Financial Services Advisors
Florida
$1.82M +$75.6K +2,325 +5%
PPA
88
Parametric Portfolio Associates
Washington
$1.81M +$201K +6,180 +15%
Creative Planning
89
Creative Planning
Kansas
$1.8M +$745K +22,896 +92%
MOACM
90
Mutual of America Capital Management
New York
$1.79M -$892K -27,415 -37%
VOYA Investment Management
91
VOYA Investment Management
Georgia
$1.79M +$315K +9,678 +26%
BCM
92
BlueCrest Capital Management
Jersey
$1.76M +$1.52M +46,764 New
Citigroup
93
Citigroup
New York
$1.75M -$1.94M -59,620 -56%
TAM
94
Tocqueville Asset Management
New York
$1.71M -$1.8M -55,300 -55%
DILIC
95
Dai-ichi Life Insurance Company
Japan
$1.55M -$52.2K -1,604 -4%
PA
96
Profund Advisors
Maryland
$1.51M +$123K +3,781 +10%
HP
97
Hikari Power
Japan
$1.51M -$651K -20,000 -33%
Legal & General Group
98
Legal & General Group
United Kingdom
$1.49M +$194K +5,973 +18%
GAM
99
Gotham Asset Management
New York
$1.46M +$1.26M +38,843 New
AQR Capital Management
100
AQR Capital Management
Connecticut
$1.46M – – –
2 3
4
5 6

ACAD Hedge Fund Activity: Q3 2017 in Review

212 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2017, worth a combined $4.44B — up 33% from $3.34B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ACAD positions and 24 closed out — a net gain of 10 holders — while 67 added to existing stakes and 72 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $74.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $44.7M.

  • 212 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2017, up from 203 in Q2 2017.
  • Funds reported $4.44B of Acadia Pharmaceuticals stock for Q3 2017, up 33% quarter-over-quarter.
  • 34 funds opened new Acadia Pharmaceuticals positions in Q3 2017 and 24 closed out, a net change of +10 holders.
  • The largest Acadia Pharmaceuticals buyer in Q3 2017 was Janus Henderson Group, an estimated $74.7M added.
  • The largest Acadia Pharmaceuticals seller in Q3 2017 was T. Rowe Price Associates, an estimated $44.7M sold.

Based on aggregated 13F filings for Q3 2017.